<DOC>
	<DOCNO>NCT01042236</DOCNO>
	<brief_summary>The hypothesis evaluation fesotorodine may provide clinical benefit treatment condition stress urinary incontinence</brief_summary>
	<brief_title>Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Female , 18 65 year SUI symptoms longer 3 month Subjects must nonpregnant breastfeed Disease medical condition affect bladder urinary tract ( tan stress urinary incontinence ) Subjects take medication effect bladder urinary tract Subejcts medical condition could adversely affected administration fesoterodine gastrointestinal tract disease , glaucoma , hepatic impairment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Phase 2 stress urinary incontinence Fesoterodine</keyword>
</DOC>